


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN, OCF_3 , OA, NHA, NA_2 , NH_2 ,

R^3, R^6 denote $(CH_2)_nHet$, $(CH_2)_nAr$,

R^1 denotes H or an organic radical, in particular
 $(CH_2)_nCO_2R^1$, $(CH_2)_nCOHet$, CHO , $(CH_2)_nOR^1$, $(CH_2)_nHet$,
 $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_n(R^1)Het$,
 $(CH_2)_nCH=N-Het$, $(CH_2)_nOOR^1$, $(CH_2)_nN(R^1)CH_2CH_2OR^5$,
 $(CH_2)_nN(R^1)CH_2CH_2OCF_3$, $(CH_2)_nN(R^1)C(R^1)OOR^5$,
 $(CH_2)_nN(R^1)CH_2COHet$, $(CH_2)_nN(R^1)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$,
 $(CH_2)_nN(R^1)CH_2CH_2N(R^1)CH_2OOR^1$, $(CH_2)_nN(R^1)CH_2CH_2N(R^5)_2$,
 $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$,
 $CH=CHCH_2OR^5$
or $(CH_2)_nN(R^1)Ar$,

R^1 denotes H or an organic radical, in particular
 $(CH_2)_nCO_2R^5$, $(CH_2)_nCOHet$, CHO , $(CH_2)_nOR^5$, $(CH_2)_nHet$,
 $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$,
 $(CH_2)_n(R^5)Het$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^1$,

$(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R^5)CH_2COHet$,
 $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$,
 $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2OCOR^5$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$,
 $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$,
 $CH=CHCH_2OR^5$
 or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical

containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or ~~monosubstituted~~ mono or polysubstituted by A and/or Hal, OR^5 , $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2 , NH_2 , $NHCOR^5$, CF_3 or SO_2CH_3 ,

X denotes CH or N.







n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I

where, in the case that X has the meaning CH, R² and R⁴ do not simultaneously denote H,

~~and/or salts, and solvates, enantiomers, racemates thereof and other or mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.~~


2. (Original) Compounds of the formula I according to Claim 1, in which R⁶ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
3. (Previously Presented) Compounds of the formula I according to claim 1, in which R⁴ denotes H, Hal, CN, A or NO₂.
4. (Previously Presented) Compounds of the formula I according to claim 1, in which R² denotes H or alkyl.
5. (Previously Presented) Compounds of the formula I according to claim 1, in which R³ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3 or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.
6. (Previously Presented) Compounds of the formula I according to claim 1, in which X has the meaning N.
7. (Original) Compounds of the formulae IA, IB, IC, ID, IE and IF:




in which

R^3 , R^4 , R^6 and X have the meanings indicated in Claim 1.

8. (Currently Amended) Process for the preparation of compounds of the formula IA




in which R^3 , R^4 , R^6 , X and A have the meaning indicated in Claim 1 ~~and/or~~ salts ~~and/or~~ solvates thereof, ~~which is characterised in that~~ comprising reacting a compound of the formula II



or acid-addition salts thereof in which

R^4 , R^6 and X have the meanings indicated in Claim 1, ~~is reacted~~ with a compound of the formula III




in which


A and R^3 have the meanings indicated in Claim 1,

~~and/or in that~~ converting a basic compound of the formula IA ~~is converted~~ into one of its salts by treatment with an acid.

9. (Currently Amended) Process for the preparation of compounds of the formula IB




in which R^3 , R^4 , R^6 , X and A have the meaning indicated in Claim 1 ~~and/or~~
~~salts and/or solvates thereof, which is characterised in that comprising~~
reacting a compound of the formula II



or acid-addition salts thereof in
 which

R^4 , R^6 and X have the meanings indicated in Claim 1, ~~is~~
~~reacted with~~ a compound of the formula IV



in which

A and R^3 have the meanings indicated in Claim 1,
 and/or ~~in that converting~~ a basic compound of the formula IB ~~is converted into one~~
 of its salts by treatment with an acid.

10. (Canceled)

11. (Currently Amended) ~~Use of the compounds of the formula I according to claim 1, and salts and solvates thereof, for the preparation of a medicament~~ A method for the treatment and/or prophylaxis of diseases which can be influenced mediated by the binding of the compounds of the formula I to 5 HT receptors, comprising administering to a host in need thereof a compound, salt, solvate, enantiomer, racemate or enantiomer mixture of claim 1.

12. (Currently Amended) ~~Use of compounds of the formula I according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method according to claim 11, wherein the salt, solvate, enantiomer, racemate or enantiomer mixture has a 5-HT receptor antagonistic action.

13. (Currently Amended) ~~Use of compounds of the formula I according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method according to claim 11, wherein the salt, solvate, enantiomer, racemate or enantiomer mixture has a 5-HT_{2A} receptor-antagonistic action.

14. (Currently Amended) ~~A Pharmaceutical composition characterised by a content of~~ comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates, and a pharmaceutically acceptable carrier.

15. (Currently Amended) ~~A P~~ process for the preparation of a pharmaceutical compositions, characterised in that comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts and/or one of its solvates is converted into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Currently Amended) ~~Use of compounds of the formula claim 1 and/or physiologically acceptable salts or solvates thereof for the~~

~~preparation of a medicament~~A method for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, ~~such as bulimia, anorexia nervosa, of~~ premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD), comprising administering to a host in need thereof a compound, salt, solvate, enantiomer, racemate or enantiomer mixture of claim 1.

17. (Currently Amended) Compounds of ~~the~~ formula I according to claim 1 in which Het denotes one of the following radicals: